Globalworld globe
United Kingdom
North America
  • facebook
  • linkedin
Medical Developments International
  • Home
  • Products
    • Asthma & COPD
    • Penthrox
    • Medical Devices
    • Veterinary
  • About
    • Distributor Information
    • Careers
    • Associations
  • Investors/Media
    • Financial Reports
    • Board of Directors/Management
    • Corporate Governance
    • Media Centre
    • Diversity Policy
    • Share Trading Policy
  • Healthcare Professionals
  • Contact

News

POST TRUMP: Business as usual – MVP signs a Respiratory deal and receives first order

Nov 13, 2016Mark EdwardsNews

14 November 2016

POST TRUMP: Business as usual – MVP signs a Respiratory deal and receives first order

Medical Developments International Limited (ASX: MVP) is delighted to announce that it has finalised a distribution deal with McKesson Corp. for the distribution of its range of ?Space Chamber? anti-static Respiratory Devices in the United States of America (USA). At the same time as concluding the agreement, McKesson placed its first order for stock which will be delivered by the end of December.

For details relating to the full ASX release, please click on the following link: mvp-signs-a-usa-respiratory-deal

Contact Us

for information on our range of products

Find a distributor

in our global network

Investors

invest in a company with
innovative foresight

News

  • Appointment of Non-Executive Director – Mary Sontrop

    5 March 2021 ASX ANNOUNCE...

  • FY21 Half Year Report and Accounts

    26 February 2021 ASX ANNO...

  • MVP Completes $25m Placement

    14 December 2020 ASX ANNO...

Healthcare Professional Registration

Login to access healthcare professional resources



Remember Me


Forgot password? | Register

Medical Developments International

Address:
4 Caribbean Drive, Scoresby,
Victoria, 3179
Australia
Phone: +61 3 9547 1888
Email: mdi@medicaldev.com
ABN: 14 106 340 667
For Medical Enquiries:

Phone: 1800 PENTHROX (1800 736 847)
Email: medinf@medicaldev.com

Email Newsletter

Sign up to our newsletter to receive MDI corporate, investor  & media news.